Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
21 oct. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative...
Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia
30 sept. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
07 sept. 2021 17h20 HE
|
Atossa Therapeutics, Inc.
Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor Atossa establishes intended criteria for non-use of additional shares for financing transactions SEATTLE, Sept. 07, 2021 ...
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
02 sept. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
13 août 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021
05 août 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia
07 juil. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease SEATTLE, July 07, 2021 (GLOBE...
Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes
16 juin 2021 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
11 juin 2021 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated
09 juin 2021 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...